HONG KONG/LONDON (Reuters) -- China's CanSino Biologics Inc reported on Thursday "positive" interim data from its experimental COVID-19 mRNA booster vaccine in a mid-stage clinical trial, as the country races to tame a severe outbreak of infections.
Infections have spiraled since China abandoned its strict "zero COVID" policy last month after protests against tight restrictions placed on its citizens.
